A detailed history of Black Rock Inc. transactions in Neuro Pace Inc stock. As of the latest transaction made, Black Rock Inc. holds 670,875 shares of NPCE stock, worth $6.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
670,875
Previous 74,154 804.71%
Holding current value
$6.2 Million
Previous $978,000 418.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.38 - $15.33 $3.81 Million - $9.15 Million
596,721 Added 804.71%
670,875 $5.07 Million
Q1 2024

May 10, 2024

SELL
$9.78 - $17.5 $120,763 - $216,090
-12,348 Reduced 14.27%
74,154 $978,000
Q4 2023

Feb 13, 2024

BUY
$5.9 - $10.31 $156,550 - $273,565
26,534 Added 44.25%
86,502 $891,000
Q3 2023

Nov 13, 2023

BUY
$4.0 - $9.73 $95,404 - $232,070
23,851 Added 66.04%
59,968 $583,000
Q2 2023

Aug 11, 2023

BUY
$3.98 - $5.12 $14,511 - $18,667
3,646 Added 11.23%
36,117 $162,000
Q1 2023

May 12, 2023

SELL
$1.44 - $5.34 $2,989 - $11,085
-2,076 Reduced 6.01%
32,471 $150,000
Q4 2022

Feb 13, 2023

BUY
$1.29 - $3.67 $11,740 - $33,400
9,101 Added 35.77%
34,547 $51,000
Q3 2022

Nov 14, 2022

BUY
$3.1 - $5.98 $10,416 - $20,092
3,360 Added 15.21%
25,446 $95,000
Q2 2022

Aug 12, 2022

SELL
$4.95 - $8.7 $1.55 Million - $2.72 Million
-313,116 Reduced 93.41%
22,086 $109,000
Q1 2022

May 12, 2022

SELL
$7.06 - $11.57 $34,488 - $56,519
-4,885 Reduced 1.44%
335,202 $2.75 Million
Q4 2021

Feb 10, 2022

BUY
$8.63 - $17.36 $52,755 - $106,121
6,113 Added 1.83%
340,087 $3.43 Million
Q3 2021

Nov 09, 2021

SELL
$15.85 - $25.07 $8,257 - $13,061
-521 Reduced 0.16%
333,974 $5.29 Million
Q2 2021

Aug 11, 2021

BUY
$19.03 - $26.5 $6.37 Million - $8.86 Million
334,495 New
334,495 $7.96 Million

Others Institutions Holding NPCE

About NeuroPace Inc


  • Ticker NPCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,846,900
  • Market Cap $230M
  • Description
  • NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...
More about NPCE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.